Montpellier, France (PRWEB) December 21, 2012
MedinCell, a leading developer of controlled release drug delivery technology, has designed a suite of long-acting painkiller products for companion animals. Based on the opiate buprenorphine, the initial MedinCell product targets pre-surgical analgesia, post-operative recovery and emergency pain relief for cats, dogs and horses. Alexandre Melin, PhD, Director of Animal Health for MedinCell, explained, “With our MedinGel pain product, dogs and cats will be able to undergo a more comfortable recovery at home following spaying, neutering or other surgeries.”
MedinCell has generated extensive data in target animal species, and will open a data room for interested parties to explore feline and canine pharmacokinetic data from our product prototypes. “Specific formulations offer analgesia for 1, 2, 3, 4 and 5 days after a single injection. This offers strategic options for partners interested in developing specific pain products for markets in North and South America, Europe, Japan, Australia and New Zealand,” Melin concluded.
Anh Nguyen, Founder and CEO of MedinCell, remarked, “This program represents one of the most ambitious reformulation projects attempted within the pain management sector since the 1980s. Over 25 million yearly surgeries are performed on pets annually across the US and Europe. Most of the available companion animal market opiates are being used off-label, and since some drugs haven’t been approved for animals, they can lead to dangerous conditions such as respiratory depression or even death.”
Nguyen continued, “Pain perception in animals is similar to humans since the same physiological mechanisms are involved. And yet, since they’re unable to display clear symptoms of pain, their need for pain control is typically underestimated. MedinCell’s pain products will offer novel tools for veterinarians that improve the lives of pets and ease concerns of pet owners. We look forward to working with animal health partners to develop these exciting products.”
MedinCell’s patent-pending drug delivery technology, MedinGel™, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration of a wide range of drug molecules. This strategy requires substantially less drug cargo than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and also designs formulations in its San Diego subsidiary, MedinCell Corporation. Contact information for both facilities is available at http://www.medincell.com.